Podcasts about disease modifying therapies

In part two of this series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss gender disparities in the treatment of multiple sclerosis.  Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

In part one of this two-part series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss what disease-modifying therapies can be safely continued and strategically timed when pregnancy is anticipated.  Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

Dr. Stacey Clardy talks with Dr. Sandra Vukusic about the disparities in treatment for female patients with multiple sclerosis, particularly focusing on how pregnancy influences treatment decisions and the overall lower exposure to disease-modifying therapies in women compared to men.  Read the related article in Neurology®.  Disclosures can be found at Neurology.org.  

While there have been improvements in therapies to treat Parkinson's symptoms, people living with the disease and their loved ones await a treatment that will slow the progression of Parkinson's disease (PD) or stop it entirely. These therapies, called disease-modifying therapies, have the potential to change how PD is treated and experienced. Tune into audio from this Third Thursdays Webinar to listen to our panel of experts discuss disease-modifying therapies and the latest in Parkinson's research. Like our podcasts? Please consider leaving a rating or review and sharing the series with your community. https://apple.co/3p02Jw0 Whether you have Parkinson's or not, you can help move research forward. Join the study that's changing everything at michaeljfox.org/podcast-ppmi. This webinar was produced with support from Biohaven. https://www.biohavenclinicaltrials.com/clinical-studies/parkinsons-disease/ Mentioned in this episode:The Foundation's landmark research study is exploring the connection between sense of smell and brain disease. People with and without Parkinson's can help by taking a free scratch-and-sniff test. Get yours at mysmelltest.org/request.

A comprehensive overview of transthyretin amyloidosis, its treatment, barriers to treatment, and future challenges to be aware of with authors, Drs. Erika L. Hellenbart and Robert J. DiDomenico. Full text of the manuscript is available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.4639.

Welcome to Living Well with MS, the podcast that empowers you to take control of your health and wellbeing. Today we're thrilled to welcome back Dr Aaron Boster as our guest! Dr Boster is a board-certified Neurologist specialising in Multiple Sclerosis. He is a frequent guest on Living Well with MS and in this episode he's here to talk about Medication, one of the pillars of the Overcoming MS Program. Specifically, Aaron goes into detail on a wide range of disease modifying therapies (DMTs) for MS, as well as discussing when people should start taking DMT's, and what they should consider before they do so. There's lots of useful information in this episode about many different DMT options – we hope you find it useful in making the right decisions for you. Let us know what you think! Watch this episode on YouTube here. Keep reading for the key episode takeaways. Topics and Timestamps: 01:21 What are the medication choices for people with MS and how have they improved? 02:39  When should I start a DMT? 04:30  What should I consider when choosing a drug? 07:08  Alemtuzumab (Lemtrada) 11:14  Cladribine (Mavenclad) 15:05  Fingolimod (Gilenya) 17:13  Mitoxantrone (Novantrone) 18:39  Natalizumab (Tysabri) 21:42  Ofatumumab (Kesimpta) 25:01  Ocrelizumab (Ocrevus) 28:58  Ozanimod (Zeposia) 30:35  Rituximab (Rituxan, MabThera, and Truxima) 32:34  Siponimod (Mayzent) 34:59  Avonex/ Betaferon/ Refib/ Extavia 37:49  Glatiramer Acetate (Copaxone) 40:07  Dimethyl Fumarate (Tecfidera) 42:38  Diroximel Fumarate (Vumerity) 43:46  Plegridy 44:45  Ponesimod (ponvory) 45:41  Teriflunomide (Aubagio) 50:14  Low-dose Naltrexone 52:07  BTK inhibitors   Want to learn more about living a full and happy life with multiple sclerosis?  Sign up to our newsletter to hear our latest tips. More info and links: Dr Boster was on six previous Living Well with MS episodes: S1E11: Making the Right Medication Choices S2E17: Lifestyle Choices and Their Impact on MS S3E43: Let's Talk About Sex (and MS) S5E5 Webinar highlights from Ask Aaron with Dr. Aaron Boster S5E36 Webinar Highlights: Ask a Neurologist with Dr Aaron Boster S6E19 Webinar Highlights: Ask a Neurologist with Dr Aaron Boster Check out Dr Boster's popular YouTube channel covering all aspects of MS New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out:  Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us:  If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS.

Welcome to Living Well with MS, the podcast that empowers you to take control of your health and wellbeing. Today we're thrilled to welcome Yvette Sargood as our guest! Yvette is an Overcoming MS facilitator and a meditation teacher who lives with MS and follows the Overcoming MS program. In this fascinating episode, Yvette talks to Geoff about meditation and mindfulness, as well as her personal journey with the MS Program, including disclosing her diagnosis to her employer and how she overcame her chocolate cravings! There's lots of useful information and tips in this episode (including a discussion on chocolate replacements!) We hope you enjoy it – let us know what you think! Watch this episode on YouTube here. Keep reading for the key episode takeaways.   Topics and Timestamps: 01:18 Yvette's MS and Overcoming MS journey 07:05 The progress made on DMTs and discrimination since the 1990s 09:01 The benefits to starting the Overcoming MS program even long after diagnosis 11:26 The decision to start a disease modifying therapy 14:59 Her difficulties in adopting the Overcoming MS program 16:27 Overcoming her chocolate cravings and chocolate replacements 18:51 Maintaining a healthy weight on the Overcoming MS program 20:23 The benefits of following the Overcoming MS program 22:54 Disclosing a multiple sclerosis diagnosis to your employer 26:01 Becoming an Overcoming MS facilitator 27:46 What is mindfulness and why is it important for people with MS? 32:53 Misconceptions about meditation and stress reduction 35:42 Tips for people new to the Overcoming MS program   Want to learn more about living a full and happy life with multiple sclerosis?  Sign up to our newsletter to hear our latest tips. More info and links: Download the Headspace app for meditation Learn more about Disease Modifying Therapies for MS Listen to a podcast featuring OMSer chef Read Yvette's article on executives and disability Learn more about mindfulness expert Jon Kabat-Zinn Join a mindfulness course with Yvette through MS-UK Become an Overcoming MS volunteer To take part in the next Pathway to Overcoming MS course email events@overcomingms.org New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out:  Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us:  If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/therapeutic-insights-navigating-the-use-and-challenges-of-disease-modifying-therapies/26346/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/breaking-ground-the-latest-data-on-ad-disease-modifying-therapies/26345/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 10-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/spinal-muscular-atrophy-optimizing-the-management-of-adults-in-the-era-of-disease-modifying-therapies/26352/ Explore this on-demand webcast for an in-depth expert presentation and case discussion. This educational initiative is designed to help neurologists enhance their clinical approach by providing individualized, evidence-based care for adult SMA patients. Gain insights into the latest treatment options, safety and efficacy data, and effective patient communication strategies. Equip yourself with the knowledge to meet the unique clinical and psychosocial needs of adults with SMA and improve patient outcomes.=

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AMU865. CME credit will be available until April 2, 2025.Navigating Advances in Alzheimer's Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AMU865. CME credit will be available until April 2, 2025.Navigating Advances in Alzheimer's Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AMU865. CME credit will be available until April 2, 2025.Navigating Advances in Alzheimer's Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AMU865. CME credit will be available until April 2, 2025.Navigating Advances in Alzheimer's Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Eisai Inc.Disclosure information is available at the beginning of the video presentation.

When people living with MS find themselves unable to continue working due to disability, they turn to Social Security Disability Insurance (SSDI). And when they do, many are surprised to find the long, winding, sometimes confusing road that lies ahead.  This week, disability law expert Jamie Hall joins me to demystify the process of applying for SSDI benefits. Jamie specializes in social security and long-term disability law. And he, literally, wrote the book for the National MS Society on applying for SSDI benefits. We'll also tell you about the amazing work this year's recipient of the Barancik Prize for Innovation in MS Research is involved in. We're reporting on the progress that scientists are making in penetrating the blood brain barrier (And we'll remind you about why that makes a real difference for everyone living with MS!) We're sharing the details about KYV-101, the experimental CAR-T cell therapy that's been given a Fast Track designation by the FDA. We'll tell you about study results that show people with a university education are more likely to be on a disease-modifying therapy. And we're sharing study results that identify the inequity in geographic proximity to MS care in the United States. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: How to apply for Social Security Disability Insurance benefits  :22 This year's recipient of the Barancik Prize for Innovation in MS research  1:58 Real progress reported in efforts to penetrate the blood brain barrier  7:17 FDA gives Fast-Track designation to CAR-T cell therapy for MS  10:03 STUDY: Having a university education makes it more likely that someone with MS will be on a DMT  13:04 STUDY: Geographic proximity to MS care in the U.S. is far from equal   15:04 Disability law expert Jamie Hall discusses how to apply for SSDI benefits   19:29 Share this episode  38:01 Have you downloaded the free RealTalk MS app?  38:21 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/336 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Applying for Social Security Disability Benefits: A Guidebook for People with MS and their Healthcare Providers https://nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Guidebook-Social-Security-Disability-for-People-with-MS.pdf Predictive High-Throughput Platform for Dual Screening of mRNA Lipid Nanoparticle Blood Brain Barrier Transfection and Crossing https://pubs.acs.org/doi/10.1021/acs.nanolett.3c03509 STUDY: University Education Facilitates Uptake of Disease-Modifying Therapies for Multiple Sclerosis: A Community-Based Study Using the UK MS Register https://journals.sagepub.com/doi/10.1177/13524585231221411 STUDY: Geographic Proximity in Access to Neurologists and Multiple Sclerosis Care in the United States https://www.neurology.org/doi/10.1212/WNL.0000000000207916 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 336 Guest: Jamie Hall, Esq. Privacy Policy

Hosts discuss a recent study on baricitinib in type 1 diabetes, how these results compare to other data in this arena, and what all of these studies mean for future of type 1 diabetes management. Episode Highlights 00:05 Intro 01:20 Baricitinib Overview 02:30 BANDIT Trial Design 03:30 Trial Results 05:40 Delaying Type 1 Diabetes 14:45 Need for Screening 18:00 Outro

Barbara S. Giesser, MD, FAAN, FANA, is an internationally recognized clinician and award-winning educator who has specialized in the care of persons with Multiple Sclerosis since 1982. Her approach to the diagnosis and management of persons with MS combines advanced diagnostics and a personalized medication plan for each patient with an emphasis on integrating lifestyle and wellness strategies into the neurologic treatment plan. Learn about disease modifying therapies for the treatment of Multiple Sclerosis in this PNI Minute.For more information: 310-582-7613 | pacificbrainhealth.org

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jay Avasarala, MD, PhD The three disease-modifying therapies for MS added into the World Health Organization's (WHO) Essential Medicines list is a great step forward for patients afflicted with this chronic disease and could also serve as a model for other neurological disorders. Dive in as Dr. Charles Turck talks to one member of the team who was responsible for submitting this list of medications, Dr. Jay Avasarala, Director of Comprehensive Care Center for Multiple Sclerosis and Neuroimmunology at the Kentucky Neuroscience Institute in Lexington.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jay Avasarala, MD, PhD The three disease-modifying therapies for MS added into the World Health Organization's (WHO) Essential Medicines list is a great step forward for patients afflicted with this chronic disease and could also serve as a model for other neurological disorders. Dive in as Dr. Charles Turck talks to one member of the team who was responsible for submitting this list of medications, Dr. Jay Avasarala, Director of Comprehensive Care Center for Multiple Sclerosis and Neuroimmunology at the Kentucky Neuroscience Institute in Lexington.

CME credits: 1.00 Valid until: 08-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/novel-and-emerging-disease-modifying-therapies-for-mild-cognitive-impairment-due-to-ad-efficacy-and-safety-of-new-dmts-for-mci/16055/ New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive impairment (MCI) and early-onset Alzheimer's disease (AD). The FDA has recently approved new disease-modifying therapies (DMTs) that slow the clinical course of MCI caused by AD. This curriculum helps clinicians identify the subtle signs and symptoms of MCI in AD. The program also helps clinicians recognize why and how racial and ethnic differences and disparities affect DMT acceptance, patient outcomes, and disease onset and progression. Faculty discuss the emerging data surrounding the novel pathways and mechanisms that drive MCI in AD and outline evidence-based treatment strategies as well as how to incorporate the new DMTs into clinical practice.

In this episode of The Just M.S. Show, we delve into the remarkable advances in the world of Multiple Sclerosis (MS) treatment and detection. From AI models predicting MS risk before symptoms appear to the groundbreaking addition of MS medications to WHO's Essential Medicines List, the hope for effective treatment is brighter than ever. We discuss the efficacy of ocrelizumab as a first-line treatment and the shift in disease-modifying therapy prescription towards oral medications. We also share personal stories of aging with MS, and the interplay between MS progression and normal aging processes. Finally, we explore fascinating research insights on how gut microbiome could trigger MS onset, and how Biogen's acquisition of Reata Pharmaceuticals might shape the future of rare disease treatments. Join us for these discussions and more as we navigate through the dynamic landscape of MS research, treatment, and personal experiences.Intro – Justin kicks off the episode by introducing the listeners to the engaging content of the day which includes the latest breakthroughs in Multiple Sclerosis (MS) treatment, research, and personal experiences.AI in Healthcare – Justin dives deep into a PRNewswire article highlighting the role of artificial intelligence (AI) and machine learning in predicting MS and minimizing laboratory errors.https://www.prnewswire.com/news-releases/artificial-intelligence-models-predict-multiple-sclerosis-detect-contaminated-lab-samples-301883543.htmlEssential Medicines Update – Discussion on the World Health Organization's new additions to the Model Lists of Essential Medicines for MS treatment, providing an analysis of how this could influence the lives of patients across the globe.https://www.who.int/news/item/26-07-2023-who-endorses-landmark-public-health-decisions-on-essential-medicines-for-multiple-sclerosisOcrelizumab Efficacy – Detailed analysis of a Healio article revealing the effectiveness of ocrelizumab as a first-line treatment for MS, backed by a comprehensive 9-year research study.https://www.healio.com/news/neurology/20230726/video-ocrelizumab-effective-as-firstline-treatment-for-msAging with MS – In this heartfelt segment, Justin presents the narrative of Trevis Gleason from Everyday Health, where he shares his personal journey with aging and MS, which many listeners will relate to.https://www.everydayhealth.com/columns/trevis-gleason-life-with-multiple-sclerosis/aging-with-ms/Prescription Shifts – Delving into a study from HealthDay News, Justin discusses the noticeable shift towards oral disease-modifying therapies in MS treatment.Gut Microbiome and MS – An exciting segment discussing research from Ludwig-Maximilians-Universität München about the relationship between the gut microbiome and the activation of auto-aggressive T cells in MS.Biogen and Reata Acquisition – In the final part of the episode, Justin tackles Biogen's recent acquisition of Reata Pharmaceuticals, offering insights into how this might shape the future of the rare disease drugs market, including MS treatment.https://www.washingtonpost.com/business/2023/07/28/biogen-deal-for-reata-signals-a-turn-to-rare-diseases/9cbf4a84-2d67-11ee-a948-a5b8a9b62d84_story.htmlOutro – Wrapping up, Justin encourages the listeners to stay positive, informed, and connected, and invites them to join the next episode of "The Just M.S. Show".Listeners are encouraged to refer to the episode description for linkThe Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.www.justmultiplesclerosis.com

Dr. Katz is the Director of the Elliot Lewis Center, and a nationally recognized expert in multiple sclerosis, neuromyelitis optica, MOG associated disease, and transverse myelitis. I've worked alongside Dr. Katz for many years and shared many patients. He's one of the few neurologists who truly listens to you and your symptoms and will spend the time to brainstorm solutions for living your best life with MS. Not only that, the Elliot Lewis Center provides cutting-edge care and access to all of the available therapeutic options and strategies. On today's episode, Dr. Katz talks about the newest disease-modifying therapy for MS, Briumvi. He shares what it is, how it works, its efficacy, how it compares to other available DMT's. Connect with Dr. Katz: Website: https://elliotlewisms.com/about-us/ Facebook: https://www.facebook.com/ElliotLewisMS Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

Robbie Gillett was at work when he became unable to move as he was installing a kitchen unit. He was convinced that he was dying or having a stroke but eventually, he was diagnosed with Multiple Sclerosis - twice!As a way to process his new reality, Robbie began writing poetry, which has been published in his first collection, Thoughts of a Warrior: Beneath the Tracksuit.In the first part of a two-part interview, Robbie talks about his journey to a definitive diagnosis, his initial experiences with Disease Modifying Therapies, and the process of finding a supportive community online.Links and resources:Connect with Robbie on Instagram, Twitter, and FacebookBuy Robbie's book, Thoughts of a Warrior: Beneath the Tracksuit Watch The Painter And The Poet on YouTube Listen to Robbie's music on SpotifyIf you're interested in having Kathy speak at your event, learn more hereFind out more about the DMAT Fitness Training programYou can find Kathy Chester at:msdisrupted@gmail.comdisruptfitnessgym@gmail.com moveitorloseit109@gmail.com Connect with @msdisrupted on Instagram, Facebook, TikTok Here are some additional products that help Kathy deal with beating the Heat and Migraines.  Take advantage of the coupon code.Koldtec - Cool Head WrapKOLD10To save $10 off every item in-store.2 items = $20 savings3 items = $30 savingshttps://www.koldtec.com/ Cold bean bag Releafpack. 15% discount use code Disrupt15https://www.releafpack.com 

ORAL MINOXIDIL IN PEDIATRICS   Jerjen R et al (starts at 12:33). Low-dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome. Br J Dermatol. 2021;184(5):977-978. Nicolas-Ruanes et al (starts at 15:33). Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. J Am Acad Dermatol. 2022 Apr 26; John JM et al (starts at 17:24). Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review. J Am Acad Dermatol . 2022 Jul 5;S0190-9622(22)02245-9.   HAIR FIBERS AND CAMOUFLAGE Ring and Keller (starts at 25:13). Effect of camouflaging agents on psychologic well-being: A cross-sectional survey of hair loss patients. J Am Acad Dermatol. 2017 Jun;76(6):1186-1189 Babadjouni A et al (starts at 28:15). Patient Satisfaction and Adverse Effects Following the use of Topical Hair Fiber Fillers. Int J Trichology. 2022 May-Jun; 14(3): 97–102   HYDROXYCHLOROQUINE IN PREGNANCY Reynolds JA et al (starts at 34:38). Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology (Oxford). 2022 Jun 29: Sperber K et al (starts at 38:25). Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 2009;7:9. Kaplan Y et al (starts at 39:17). Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 May;81(5):835-48. Clowse MEB et al (starts at 40:27). Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med. 2022 Mar;9(1):e000651. Huybrechts K et al (starts at 42:37). Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol 2021 Mar;224(3):290.e1-290.e22 Huybrechts K et al (starts at 45:20). Hydroxychloroquine early in pregnancy and risk of birth defects: absence of evidence is not the same as evidence of absence. Am J Obstet Gynecol. 2021 May;224(5):549-550. Bérard et al (starts at 46:58). Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence. Front Pharmacol. 2021 Aug 2;12:722511. Howley et al (starts at 47:17). Maternal exposure to hydroxychloroquine and birth defects. Birth Defects Res. 2021 Oct 15;113(17):1245-1256. Andersson et al (starts at 47:34). Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology (Oxford). 2021 May 14;60(5):2317-2326.   TERIFLUNOMIDE INDUCED HAIR LOSS IN MULTIPLE SCLEROSIS Travis LH et al (starts at 53:28). Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice? Neurol Ther. 2018 Dec; 7(2): 341–347. Porwal MH et al (starts at 55:41). Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies. J Cent Nerv Syst Dis. 2022 Jun 23;14:11795735221109674.   DO IT YOURSELF LOW-ALLERGEN PRODUCTS Xiong M and Warshaw EM. (starts at 1:05:45) Hair Care Product Hacks: Do It Yourself Alternatives. Dermatitis. 2022 Jun 29. Zirwas M and Moennich J (starts at 1:00:25). Shampoos. Dermatitis. 2009 Mar-Apr;20(2):106-10 Tawfik M, Rodriguez-Homs LG, Alexander T, et al (starts at 1:01:10). Allergen content of  best-selling ethnic versus nonethnic shampoos, conditioners, and styling products. Dermatitis 2021;32(2):101–110 https://donovanmedical.com/diy   PREMATURE GREYING (EARLY CANITIES) Anggraini et al (starts at 1:08:50). Risk Factors Associated with Premature Hair Greying of Young Adult. Open Access Maced J Med Sci . 2019 Nov 14;7(22):3762-3764. Dawber RP (starts at 1:09:12). Integumentary associations of pernicious anaemia. Br J Dermatol . 1970 Mar;82(3):221-3. Mosley JG and Gibbs AC (starts at 1:09:50). Premature grey hair and hair loss among smokers: a new opportunity for health education? British Medical Journal 1996; 313: 1616. Bhat RM et al (starts at 1:10:21). Epidemiological and investigative study of premature graying of hair in higher secondary and pre-university school children. Int J Trichology. 2013;5:17–21. Chang H-C and Sung C-W (starts at 1:10:35). Association between serum levels of minerals and premature hair graying: a systematic review and meta-analysis. Int J Dermatol. 2020 Oct;59(10):e378-e380. Schnohr P et al (starts at 1:12:35). Longevity and gray hair, baldness, facial wrinkles, and arcus senilis in 13,000 men and women: The Copenhagen city heart study. J Gerontol A Biol Sci Med Sci. 1998;53:M347–50. Schnohr P et al. Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. Am Heart J  1995 Nov;130(5):1003-10.   Kocaman SA et al (starts at 1:14:10) . The degree of premature hair graying as an independent risk marker for coronary artery disease: A predictor of biological age rather than chronological age. Anadolu Kardiyol Derg 2012;12:457-63.  Paik S et al (starts at 1:14:25). Association Between Premature Hair Greying and Metabolic Risk Factors: A Cross-sectional Study. Acta Derm Venereo. 2018 Aug 29;98(8):748-752. Mahendiratta S et al (starts at 1:15:09). Premature graying of hair: Risk factors, co-morbid conditions, pharmacotherapy and reversal-A systematic review and meta-analysis. Dermatol Ther. 2020 Nov;33(6):e13990. Das S et al (starts at 1:15:51) Cardiovascular risk markers in premature canities. Indian J Dermatol Venereol Leprol. 2022 Jun 30;1-5.

Join our conversation to hear how a toxin that's commonly used for cosmetic purposes is a game changer for Jennifer in managing her MS-induced neurogenic bladder. She had her second-ever Botox treatment on July 12, and these treatments have given her increased urinary continence and confidence. And this twice-a-year procedure is just one way Jennifer is showing this disease who's boss. Listen to learn what led her to consider this form of treatment, how her previous experiences with MS disease-modifying therapies instilled the confidence to move forward with Botox, and what her advice is for anybody with MS who is looking into this option for treating MS-related incontinence issues.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Dr. Daniel Hartung discusses the association between Medicare Part D Plan disease-modifying therapy restrictiveness and adherence and outcomes among people with multiple sclerosis. Show references: https://cp.neurology.org/content/12/1/36 https://www.neurology.org/podcast

Dr. Justin Abbatemarco talks with Dr. Daniel Hartung about the impact of Medicare Part D plan disease-modifying therapy restrictiveness upon adherence and outcomes among patients with multiple sclerosis. Read the full article in Neurology: Clinical Practice.

I'm delighted that my guests today are Tamara Kahn and Terry Hord, twin sisters who both have MS. Following their diagnosis, they have been navigating their lives with secondary Progressive MS and advocating through work for the National MS Society, their Twins Coast 2 Coast website, and on Instagram.In the first of a two-part interview, they talk about being diagnosed with the same chronic illness, married life, changes they've seen in Disease Modifying Therapies, and how their advocacy work is inspired by their mother's death from a rare form of cancer. The resilience she showed is a legacy that lives on, not only through Tamara and Terry but their own children. Links and resources:Visit Tamara and Terry at Twins Coast 2 CoastVisit the National MS Society and find out more about the Navigator Program You can find Kathy Chester atdisruptfitnessgym@gmail.com moveitorloseit109@gmail.com Instagram - @msmoveitorloseit @disruptfitnessgymHere are some additional products that help Kathy deal with beating the Heat and Migraines.  Take advantage of the coupon code.Koldtec - Cool Head WrapKOLD10To save $10 off every item in store.2 items = $20 savings3 items = $30 savingshttps://www.koldtec.com/ Cold bean bag Releafpack. 15% discount use code Disrupt15https://www.releafpack.com 

If you're living with MS, you know by now that quitting smoking, getting exercise, and making smart food choices have all been shown to improve your physical health and your quality of life. There's one more tool that, when necessary, can be a game-changer.  Joining me to talk about how assistive technology can help people living with MS maintain their independence and improve their quality of life are assistive technology experts Alex Burnham and Bill Binko.  We'll also share one more reason why your most important preparation for the holiday season this year is making sure you're fully vaccinated. We'll tell you about the International Progressive MS Alliance's proposal for coordinating global progressive MS research. We'll share the results of a study that shows a significant percentage of older people living with MS who discontinue their DMT experience disease worsening and progression. We'll tell you about a new grant that's been awarded to study adherence to MS oral disease-modifying therapies. And you'll hear about the results of a study that shows an association between low levels of vitamin D and cognitive dysfunction at the onset of MS. We have a lot to talk about! Are you ready for RealTalk MS??! There's a new reason to be vaccinated!  3:43 International Progressie MS Alliance's proposal for a global progressive MS research agenda   6:57 My goodbye to the Progressive MS Alliance Scientific Steering Committee  8:16 A study shows that older people who discontinue DMTs suffer disease worsening and progression  9:56 Researcher receives $100,000 to study MS oral DMT adherence  12:39 A study shows low levels of Vitamin D are associated with cognitive dysfunction at the onset of MS  15:22 Alex Burnham and Bill Binko discuss how assistive technology can be a difference-maker for people living with MS   18:51 Share this episode  37:47 Have you downloaded the free RealTalk MS app???  38:08 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/223 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance National MS Society Third COVID-19 Vaccine Dose Guidance for People Living with MS https://www.nationalmssociety.org/About-the-Society/News/Additional-COVID-19-Vaccine-Dose-(Booster)-and-MS Charting a Global Research Strategy for Progressive MS -- An International Progressive MS Alliance Proposal https://journals.sagepub.com/doi/10.1177/13524585211059766 STUDY: Discontinuation of Disease-Modifying Therapies is Associated with Disability Progression Regardless of Prior Stable Disease and Agehttps://www.msard-journal.com/article/S2211-0348(21)00673-8/fulltext STUDY: Real World Adherence To, and Persistence With, Once- and Twice-Daily Oral Disease Modifying Drugs in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysishttps://bmcneurol.biomedcentral.com/articles/10.1186/s12883-020-01830-0 STUDY: Serum Vitamin D as a Marker of Impaired Information Processing Speed and Early Disability in Multiple Sclerosis Patientshttps://www.mdpi.com/2076-3425/11/11/1521/htm Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 223 Guests: Alex Burnham and Bill Binko Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

Summertime traditionally means getting out of the house, enjoying outdoor activities, and being active. But if you're living with MS, outdoor activity and summertime temperatures can raise red flags when it comes to your day-to-day quality of life. My guest is Dr. Colin Lenington, an Occupational Therapist and Clinical Specialist at the VA Long Beach Healthcare System and we're talking about getting outside, staying safe, and keeping cool while you enjoy your summer activities. We're joining the World Federation of Neurology and the global MS community on July 22nd, to celebrate World Brain Day 2021. This year's theme is Stop Multiple Sclerosis and we'll tell you where and how to register for the upcoming World Brain Day webinar. We're also talking about study results that show the impact of delaying an Ocrevus infusion in order to enhance the effect of a COVID-19 vaccination. We'll tell you about a study in the U.K. that followed 120 people with MS who received autologous hematopoietic stem cell transplantation (aHSCT). We'll share news about a new way to successfully cross the blood-brain barrier and deliver medicines to the central nervous system. (And we'll explain why that matters when it comes to treating MS) And we'll tell you about a study of veterans with MS that should convince anyone to adhere to their DMT treatment plan. We have a lot to talk about! Are you ready for RealTalk MS??! July 22nd is World Brain Day!  :22 My live conversation with Dr. Victoria Leavitt takes place this Wednesday, on the eSupport Health Wednesday Workshop   :55 Study shows the effect of extended interval dosing of Ocrevus  2:46 Study shows real-world outcomes for 120 people with MS who received aHSCT  5:49 Biopharmaceutical company successfully delivers an anti-inflammatory molecule across the blood-brain barrier  7:43 Study shows the benefits of adhering to DMTs  9:03 Dr. Colin Lenington talks about how to enjoy summertime activities while staying safe and staying cool  11:24 Share this episode  24:25 Catch my live conversation with Dr. Victoria Leavitt on Wednesday  24:48 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/203 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance World Brain Day 2021 https://wfneurology.org/world-brain-day-2021 Register for the eSupport Health Wednesday Workshop: A Conversation with Jon Strum https://esupporthealth.zoom.us/meeting/register/tJEpc--rqT0vHdJ6FbPDH7S1enOrLYAIQG-K STUDY: Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19https://nn.neurology.org/content/8/5/e1035 STUDY: Autologous Haematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-World Case Serieshttps://n.neurology.org/content/early/2021/07/12/WNL.0000000000012449 Bioasis Announces Positive Results from Efficacy Study of xB3TM -1L-1RA in a Model of Multiple Sclerosis https://www.globenewswire.com/news-release/2021/07/07/2259430/0/en/Bioasis-Announces-Positive-Results-From-an-Efficacy-Study-of-xB3-IL-1RA-in-a-Model-of-Multiple-Sclerosis.html STUDY: The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis https://journals.sagepub.com/doi/pdf/10.1177/11795735211028769 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Androidhttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 203 Guest: Dr. Colin Lenington Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

This week, and for the foreseeable future, we're committed to sharing the most updated and reliable information on COVID-19 and MS. Joining me as my guest is Dr. Marwa Kaisey, an Assistant Professor of Neurology specializing in Multiple Sclerosis and Neuroimmunology at Cedars-Sinai in Los Angeles. We're talking with Dr. Kaisey about the things that people need to know about Ocrevus, Tecfidera, Gilenya, and other specific MS disease-modifying therapies in light of COVID-19. Dr. Kaisey will also share information about the status of people living with MS who have already been diagnosed with COVID-19. And we'll even hear about some MS disease-modifying therapies that are being tested as potential treatments for COVID-19. We'll connect you to the video replay of last Friday's Ask An MS Expert webinar. I hope you already consider these weekly webinars with leading MS experts answering your questions to be "can't miss" viewing. We're also talking about the federal government's decision not to re-open enrollment for health insurance under the Affordable Care Act for 39 states, and we'll tell you which 11 states have re-opened enrollment during the pandemic. And we'll share the federal government's guidance, reminding states, healthcare providers, and healthcare facilities that it's a violation of federal law to withhold medical treatment due to disability. (We're also sharing a link to that document that you can download and keep with you on your phone!) We'll review the specific provisions in the Coronavirus Aid, Relief, and Economic Security Act that MS Activists advocated for. And we'll talk about how COVID-19 is already delaying the development and distribution of new MS disease-modifying therapies. We have a lot to talk about! Are you ready for RealTalk MS??! ___________ Check out Episode 3 of the National MS Society's Ask an MS Expert Webinar Series 1:04 Federal government refuses to re-open Affordable Care Act enrollment during pandemic 3:06 Federal government issues guidance to avoid healthcare discrimination based on disability 5:09 COVID-19 is impacting drug development 10:24 My Interview with Dr. Marwa Kaisey 12:00 Share this episode 23:32 Donate to Walk-MS 23:58 ___________ SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/136 ___________ ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.comPhone: (310) 526-2283 ___________ LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Give RealTalk MS a Rating & Review National MS Society's Ask An MS Expert Video Replay What You Need to Know About Coronavirus (COVID-19) COVID-19 Resources for Caregivers The RealTalk MS Continuing the Conversation Facebook Group BULLETIN: Civil Rights, HIPAA, and the Coronavirus Disease 2019 (COVID-19) Federal Coronavirus Response and Economic Stimulus Information Jon's WALK-MS Fundraising Page Download the RealTalk MS App for iOS Download the RealTalk MS App for Android Give RealTalk MS a Rating & Review ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 136 Hosted By: Jon Strum Guests: Dr. Marwa Kaisey Tags: MS, MultipleSclerosis, MSResearch, MSActivist, MSSociety, Ocrevus, Coronavirus, COVID19, RealTalkMS Privacy Policy

MS News Today columnist and forums moderator Ed Tobias discusses the impact of the noval coronavirus on people with MS who are using disease-modifying therapies. Are you interested in learning more about Multiple Sclerosis? If so, please visit https://multiplesclerosisnewstoday.com/